Close Menu

Lung Cancer

News and reporting on lung cancer.

The project is collaborating with nine biopharma companies to combine more real-world clinical data with genomic data.

The company said it can now market test kits for both liquid biopsy and FFPE samples to labs in the EU and other participating geographies.

The firm will offer 4.7 million shares of its stock at $2.27 per share. Proceeds will go toward the development and commercialization of its tests.

Inivata expects to publish initial data on the assay's detection abilities in lung cancer at the American Association for Cancer Research virtual meeting in July.

In Q1, the US represented more than 40 percent of new Idylla instrument placements, but growth stalled due to COVID-19.

The agreement reflects Oncocyte's strategy to establish distribution partners with existing oncology channels to extend the reach of its tests globally.

The firm said as part of a development study it is using a gut microbiome analysis tool developed in collaboration with Thermo Fisher Scientific.

The Cold Spring Harbor Laboratory spinout will build predictive models for lung cancer progression and risk using its SpliceCore software platform.

The firms will evaluate Stratafide, a pan-solid tumor diagnostic test designed to identify actionable genomic alterations in tissue or blood samples.

A new paper outlines an upcoming effort to trace tumor development and trajectory in time and space using single-cell genetics and other genomic methods.

Pages

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.